The Salk Institute for Biological Studies is embarking on an exciting journey to revolutionize therapy delivery with sonogenetics, a technique that utilizes low-intensity ultrasound for precise control over cellular proteins. Recently, the institute announced the receipt of $41.3 million in funding from the Advanced Research Projects Agency for Health (ARPA-H). This funding will support the development of sonogenetics as a potential treatment for various conditions, particularly starting with peripheral neuropathies.
The Vision of Drug-Free Therapy
Sreekanth Chalasani, a lead researcher at Salk and co-founder of SonoNeu, expressed enthusiasm about this funding, noting that it represents a significant step towards achieving a drug-free method of delivering therapy in a targeted manner. By integrating engineered ultrasound-sensitive proteins with wearable ultrasound technology, the goal is to provide treatment precisely where and when it is needed, moving away from traditional pharmaceutical approaches.
Pioneering Research in Sonogenetics
Chalasani’s journey into sonogenetics began in 2011 with support from Salk’s Innovation and Collaboration Grants program. His team developed a method to sensitize specific cell types to ultrasound by introducing ultrasound-responsive proteins. In 2015, they identified a protein from the roundworm Caenorhabditis elegans that made cells responsive to low-frequency ultrasound. This breakthrough enabled the activation of neurons using ultrasound waves, paving the way for further exploration into mammalian cell manipulation.
Accelerated Progress Towards Clinical Application
According to Chalasani, the rapid advancement from concept to potential clinical applications is noteworthy, particularly compared to the typical lengthy timelines associated with new therapies. He attributes this swift progress to the collaborative efforts of trainees, post-doctoral researchers, and the early support from institutions like the National Institutes of Health’s Brain Initiative, which played a crucial role in the project’s advancement.
Collaborative Research Efforts
The next phase of developing sonogenetics involves a diverse array of institutions and expert teams. Collaborators include Scripps Research, where Nobel Laureate Ardem Patapoutian will assist in discovering and engineering ultrasound-sensitive proteins. Other partnerships involve teams from St. Boniface Hospital Research, Duke University, Massachusetts Institute of Technology, and the University of California, San Diego, all contributing specialized knowledge to advance this innovative technology.
Exploring New Frontiers in Protein Activation
Chalasani and his team at Salk are focused on identifying additional ultrasound-sensitive proteins that can be optimized for specific therapeutic applications. These proteins, which can facilitate the entry of calcium and chloride into cells upon ultrasound stimulation, are termed ultrasound actuators. The research team aims to discover proteins that can activate various signaling pathways to enhance therapeutic efficacy.
Validation and Future Applications
The research will also include validation studies in mouse models, with plans to extend experiments to larger animal models, such as pigs. A portion of the ARPA-H funding will go towards the commercialization of therapies derived from sonogenetics technology through the Salk spinout, SonoNeu, with the ambitious goal of progressing towards U.S. Food and Drug Administration approval within five years.
Target Conditions and Future Prospects
The initial focus will be on treating peripheral neuropathies, but the potential applications of sonogenetics extend far beyond. Chalasani mentions possibilities for patients with diabetes, heart conditions, and even bladder control issues. There are also intriguing prospects for brain-computer interfaces, showcasing the versatility and transformative potential of this technology.
Conclusion
The advancements in sonogenetics hold great promise for the future of noninvasive therapeutic interventions. With a dedicated team and substantial funding, the Salk Institute is poised to lead the charge in developing innovative treatments that could redefine how we approach various medical conditions. The journey from research to real-world application is ambitious, but the potential benefits for patients are substantial.
- Takeaway Points:
- Salk Institute secures $41.3 million funding for sonogenetics research.
- Aims to create noninvasive therapies using ultrasound technology.
- Collaborative efforts involve multiple prestigious institutions.
- Initial focus on peripheral neuropathies with broader applications anticipated.
- Commercialization plans target FDA approval within five years.
Read more → www.genengnews.com